

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	ICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/608,170	06/26/2003		Cathy Klech Gelotte	MCP 275 CON 2	8241
27777	7590	04/27/2005	EXAMINER		
PHILIP S.			JAGOE, DONNA A		
JOHNSON ONE JOHN		SON OHNSON PLAZA	ART UNIT	PAPER NUMBER	
		NJ 08933-7003	1614		
				DATE MAILED: 04/27/200	5

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
. •	10/608,170	GELOTTE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Donna Jagoe	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	86(a). In no event, however, may a reply be till within the statutory minimum of thirty (30) day rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	mely filed ys will be considered timely. In the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 28 Ja	nuary 2005.					
	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) <u>18-42</u> is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) <u>18-42</u> is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
	•					
Attachment(s) 1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail D	ate				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5)	Patent Application (PTO-152)				

Art Unit: 1614

The amendment to the specification filed 28 January 2005 has been received and entered. Claims 18-42 are pending. The rejection of claim 28 made in the paper mailed 1 November 2004 under 35 U.S.C. §102(b) over Sunshine '465 ("Sunshine 1") is maintained and hereby repeated for the reasons set forth in the previous office action and those set forth below.

Applicant asserts that in making the rejection the examiner is required to point to the disclosure in the reference "by page and line", which the examiner has done. If there is any portion of the rejection that applicant does not understand, the applicant is encouraged to telephone the examiner. The phone number is provided below. Further, Applicant does not seem to be able to fine where a suspension is found in the Sunshine reference cited. It appears in column 12, line 57 bridging to line 58. If applicant's objection is to the lack of the word "stable", it is unclear why any manufacturer would make an "unstable" suspension. By nature, all suspensions fall out and must be shaken before use, however this is not "unstable". It is merely a suspension by definition.


The rejection of claims 28-41 made in the paper mailed 1 November 2004 under 35 U.S.C. §103(a) over Sunshine '899 ("Sunshine 2") is maintained and hereby repeated for the reasons set forth in the previous office action and those set forth below.

In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does

Art Unit: 1614

not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). It is well known that ibuprofen is insoluble in water and must be formulated into a suspension, as evidenced by the plethora of suspension formulations of ibuprofen in the marketplace.

The following prior art pertinent to applicant's disclosure is made of record and not relied upon.



Art Unit: 1614

SOLUBILITY IN WATE	R Practically insoluble
рН	
VAPOR DENSITY	
VALOR DEIXSIT	
AUTOIGNITION	
NFPA RATINGS	
REFRACTIVE INDEX	
FLASH POINT	
CT A DILITY	Chalata a madan a cultura a canaditira a
STABILITY	Stable under ordinary conditions

Further, regarding applicant's assertion that water is not contained in the composition, Sunshine et al. teach syrup formulations. The definition of a syrup, according to The American Heritage® Stedman's Medical Dictionary Copyright © 2002, 2001, 1995 by Houghton Mifflin Company is a concentrated solution of sugar in water, often used as a vehicle for medicine. Thus, even though water is not specifically recited, the presence of a syrup would include the presence of water.

The obviousness type double patenting rejection of claims 18-27 made in the paper mailed 1 November 2004 over claims 1-13 of U.S. 6,211,246 is maintained and hereby repeated for the reasons set forth in the previous office action. Since there are no other rejections are pending, these claims would be allowable with a timely filed terminal disclaimer.

The obviousness type double patenting rejection of claims 29-41 made in the paper mailed 1 November 2004 over claims 23-30 of U.S. 6,211,246 is maintained and hereby repeated for the reasons set forth in the previous office action.

The obviousness type double patenting rejection of claim 42 made in the paper mailed 1 November 2004 over claim 14 of U.S. 6,211,246 is maintained and hereby

Art Unit: 1614

repeated for the reasons set forth in the previous office action. Since there are no other rejections are pending, this claim would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims and with a timely filed terminal disclaimer.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna Jagoe whose telephone number is (571) 272-0576. The examiner can normally be reached on Monday through Thursday from 9:00 A.M. - 3:00 P.M..

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571) 272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Donna Jagoe Patent Examiner Art Unit 1614

04/25/2005

CHRISTOPHER S. F. LOW SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1800